CG Oncology vs Fate Therapeutics
Fate Therapeutics is the larger business, with $6.6m of revenue in fiscal 2025 against $4.0m for CG Oncology (1.6 times as much). CG Oncology grew faster (254.7% against -51.2%). Fate Therapeutics kept more of each dollar of sales as profit: a net margin of -2051.1% against -3985.0%. Fate Therapeutics carries less debt relative to equity (0.0% against 0.4%).
| Latest fiscal year | CG OncologyCGON, 2025 | Fate TherapeuticsFATE, 2025 |
|---|---|---|
| Revenue | $4.0m | $6.6m |
| Revenue growth | 254.7% | -51.2% |
| Net income | −$161m | −$136m |
| Operating margin | -4722.1% | -2222.4% |
| Net margin | -3985.0% | -2051.1% |
| Return on equity | -21.7% | -51.8% |
| Free cash flow | −$132m | −$112m |
| Cash | $32.5m | $46.6m |
| Total debt | $3.0m | $0 |
| Debt to equity | 0.4% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 142 | 161 |
| Market value | $5.69bn | $236m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 1 buys, 17 sales | 0 buys, 6 sales |